Log in

Insmed Stock Forecast, Price & News

+0.19 (+0.57 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $33.37
50-Day Range
MA: $28.36
52-Week Range
Now: $33.37
Volume2.25 million shs
Average Volume1.15 million shs
Market Capitalization$3.39 billion
P/E RatioN/A
Dividend YieldN/A
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Read More
Insmed logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:INSM



Sales & Book Value

Annual Sales$136.47 million
Book Value$2.93 per share


Net Income$-254,340,000.00
Net Margins-147.54%


Market Cap$3.39 billion
Next Earnings Date11/4/2020 (Estimated)
+0.19 (+0.57 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Insmed (NASDAQ:INSM) Frequently Asked Questions

How has Insmed's stock price been impacted by Coronavirus (COVID-19)?

Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INSM shares have increased by 57.0% and is now trading at $33.37.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Insmed?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Insmed

When is Insmed's next earnings date?

Insmed is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Insmed

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.06. The biopharmaceutical company had revenue of $42.50 million for the quarter, compared to analyst estimates of $34.51 million. Insmed had a negative return on equity of 82.15% and a negative net margin of 147.54%. Insmed's quarterly revenue was up 41.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.81) earnings per share.
View Insmed's earnings history

What price target have analysts set for INSM?

8 equities research analysts have issued 1 year target prices for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's share price to reach $42.38 in the next twelve months. This suggests a possible upside of 27.0% from the stock's current price.
View analysts' price targets for Insmed

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (GILD), AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Opko Health (OPK), ACADIA Pharmaceuticals (ACAD), NVIDIA (NVDA), Alibaba Group (BABA), Amarin (AMRN) and Micron Technology (MU).

Who are Insmed's key executives?

Insmed's management team includes the following people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.72%), Vanguard Group Inc. (9.26%), Bellevue Group AG (1.43%), Holocene Advisors LP (1.09%), First Light Asset Management LLC (1.01%) and Fairmount Funds Management LLC (1.00%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis.
View institutional ownership trends for Insmed

Which institutional investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Ikarian Capital LLC, Bellevue Group AG, Hudson Bay Capital Management LP, Fairmount Funds Management LLC, Mutual of America Capital Management LLC, Virtus ETF Advisers LLC, and SG Americas Securities LLC. Company insiders that have sold Insmed company stock in the last year include John Goll, John Soriano, Melvin Md Sharoky, and Orlov S Nicole Schaeffer.
View insider buying and selling activity for Insmed

Which institutional investors are buying Insmed stock?

INSM stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Sofinnova Investments Inc., Candriam Luxembourg S.C.A., Frontier Capital Management Co. LLC, Holocene Advisors LP, Principal Financial Group Inc., and Principal Financial Group Inc.. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis.
View insider buying and selling activity for Insmed

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $33.37.

How big of a company is Insmed?

Insmed has a market capitalization of $3.39 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

What is Insmed's official website?

The official website for Insmed is www.insmed.com.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.